Table 1.
Baseline Characteristics of Included Trials
| Trial | Country | Centers | Patients | Sample Size | Treatment Onset, Month | Treatment Duration, Month | Male, % | Mean Age, Y | Follow-Up, Mo | Lost to Follow-Up, % | Blinding |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AAASPS 20035 | US | 62 | IS | 1809 | 0.25 to 3 | 19 (mean) | 47 | 61 | 19 (mean) | 3.8 | Double-blind |
| ACCSG 19856 | US and Canada | 15 | TIA | 890 | <3 | 18 (median) | 67 | 63 | 25 (median) | 4.2 | Double-blind |
| AICLA 19837 | France | 4 | IS, TIA | 400 | <12 | 36 | 69 | 63 | 36 | 3.8 | Double-blind |
| CAPRIE 19968 | Worldwide | 384 | IS | 6431 | 0.25 to 6 | 20 (mean) | 64 | 65 | 23 (mean) | 0.7 | Double-blind |
| CASISP 20089 | China | 13 | IS | 719 | 1 to 6 | 12 to 18 | 69 | 60 | 12 (mean) | 1.3 | Double-blind |
| CHARISMA 201110 | Worldwide | 768 | IS, TIA | 4320 | <60 | 25 (median) | 63 | 65 | 25 (median) | 0.5 | Double-blind |
| CSPS2 201011 | Japan | 278 | IS | 2672 | <7 | 12 to 60 | 72 | 64 | 29 (mean) | 0.2 | Double-blind |
| ESPRIT 200612 | Worldwide | 79 | Minor IS, TIA | 2739 | <6 | 42 (mean) | 66 | 63 | 42 (mean) | 3.8 | Open |
| ESPS2 199613 | Europe | 59 | IS, TIA | 4953 | <3 | 24 | 58 | 67 | 24 | 0.6 | Double-blind |
| Fukuuchi 200714 | Japan | 129 | IS | 1151 | >0.25 | 52 | 73 | 65 | 52 | NS | Double-blind |
| Guo 200915 | China | 1 | IS | 68 | 1 to 6 | 12 | 35 | 61 | 12 | NS | NS |
| Hass 198916 | US and Canada | 56 | IS, TIA, RI | 3069 | <3 | 27 (mean) | 65 | 63 | 24 to 72 | 2.7 | Double-blind |
| JASAP 201117 | Japan | 157 | IS | 1294 | 0.25 to 6 | 15 (mean) | 72 | 66 | 24 | 0.2 | Double-blind |
| Li 200018 | China | 9 | IS, TIA | 329 | NS | 12 (mean) | 71 | 64 | 12 (mean) | 2.4 | NS |
| MATCH 200419 | Worldwide | 507 | IS, TIA | 7599 | <3 | 18 | 63 | 66 | 18 | 4.3 | Double-blind |
| Matias-Guiu 198720 | Spain | 1 | TIA | 186 | <12 | 21 (mean) | 77 | 55 | 21 (mean) | 4.5 | Open |
| PERFORM 201121 | Worldwide | 802 | IS, TIA | 19 100 | <3 | 28 (mean) | 63 | 67 | 28 (mean) | 0.3 | Double-blind |
| PRoFESS 200822 | Worldwide | 695 | IS | 20 332 | <3 | 30 (mean) | 64 | 66 | 30 (mean) | 0.6 | Double-blind |
| S-ACCESS 200823 | Japan | 14 | IS | 1499 | 0.25 to 6 | 19 (mean) | 72 | 65 | 19 (mean) | NS | Double-blind |
| SPS3 201224 | Worldwide | 82 | IS | 3020 | <6 | 41 (mean) | 63 | 63 | 41 (mean) | 2.0 | Double-blind |
| TACIP 200325 | Portugal and Spain | 43 | IS, TIA | 2107 | <6 | 12 to 36 | 66 | 65 | 30 (mean) | 2.1 | Double-blind |
| TAPIRSS 200426 | Argentina | 19 | IS, TIA | 429 | <6 | 19 (mean) | 68 | 65 | 19 (mean) | NS | Double-blind |
| Tohgi 198727 | Japan | 101 | TIA | 281 | <3 | 36 | NS | NS | 36 | NS | 12-mo double-blind, ≥24-mo open |
| TOPALS 200328 | Japan | 25 | IS, TIA | 270 | <6 | 19 (mean) | 65 | 67 | 19 (mean) | NS | NS |
IS indicates ischemic stroke; NS, not specified; RI, retinal ischemia; TIA, transient ischemic attack.